Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free GNLX Stock Alerts

Genelux (GNLX) Financials

Genelux logo
$2.56 +0.06 (+2.40%)
Closing price 04:00 PM Eastern
Extended Trading
$2.56 +0.00 (+0.20%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Genelux

Annual Income Statements for Genelux

This table shows Genelux's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.21 -28 -30 -32
Consolidated Net Income / (Loss)		 -5.21 -28 -30 -32
Net Income / (Loss) Continuing Operations		 -5.21 -28 -30 -32
Total Pre-Tax Income 		-4.11 -28 -30 -32
Total Operating Income		 -3.01 -24 -32 -33
Total Gross Profit		 11 0.17 0.01 0.01
Total Revenue		 11 0.17 0.01 0.01
Operating Revenue		 11 0.17 0.01 0.01
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 24 32 33
Selling, General & Admin Expense		 5.00 12 13 13
Research & Development Expense		 9.08 13 19 20
Total Other Income / (Expense), net		 -1.09 -4.13 1.83 1.07
Interest & Investment Income		 0.00 0.18 0.70 0.71
Other Income / (Expense), net		 0.31 -3.15 1.13 0.36
Basic Earnings per Share		 ($0.57) ($1.16) ($0.95) ($0.86)
Weighted Average Basic Shares Outstanding		 9.12M 24.43M 31.45M 37.18M
Diluted Earnings per Share		 ($0.57) ($1.16) ($0.95) ($0.86)
Weighted Average Diluted Shares Outstanding		 9.12M 24.43M 31.45M 37.18M
Weighted Average Basic & Diluted Shares Outstanding		 - 26.87M 34.60M 44.81M

Quarterly Income Statements for Genelux

This table shows Genelux's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.77 -7.85 -6.58 -6.47 -8.98 -7.49 -7.46 -7.95 -9.25 -8.93 -9.47
Consolidated Net Income / (Loss)		 -6.77 -7.85 -6.58 -6.47 -8.98 -7.49 -7.46 -7.95 -9.25 -8.93 -9.47
Net Income / (Loss) Continuing Operations		 -6.66 -7.85 -6.58 -6.47 -8.98 -7.49 -7.46 -7.95 -9.25 -8.93 -9.47
Total Pre-Tax Income 		-6.66 -7.85 -6.58 -6.47 -8.98 -7.49 -7.46 -7.95 -9.25 -8.93 -9.47
Total Operating Income		 -7.00 -8.12 -6.89 -6.94 -9.75 -7.82 -7.79 -8.19 -9.41 -9.17 -9.65
Total Gross Profit		 - 0.01 0.00 0.00 - 0.00 0.00 0.00 0.01 0.00 0.00
Total Revenue		 - 0.01 0.00 0.00 - 0.00 0.00 0.00 0.01 0.00 0.00
Operating Revenue		 - 0.01 0.00 0.00 - 0.00 0.00 0.00 0.01 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 7.00 8.12 6.89 6.94 9.75 7.82 7.79 8.19 9.42 9.17 9.65
Selling, General & Admin Expense		 2.84 4.11 2.48 2.89 3.23 3.12 3.03 3.45 3.77 3.39 3.14
Research & Development Expense		 4.16 4.01 4.42 4.05 6.52 4.70 4.76 4.74 5.65 5.78 6.51
Total Other Income / (Expense), net		 0.23 0.27 0.32 0.47 0.77 0.32 0.34 0.24 0.17 0.24 0.17
Interest & Investment Income		 0.18 0.11 0.16 0.22 -0.36 0.18 0.22 0.18 0.13 0.17 0.13
Other Income / (Expense), net		 - 0.15 0.15 0.25 1.13 0.14 0.11 0.07 0.04 0.07 0.05
Basic Earnings per Share		 ($0.20) ($0.29) ($0.22) ($0.19) ($0.25) ($0.21) ($0.20) ($0.21) ($0.24) ($0.20) ($0.21)
Weighted Average Basic Shares Outstanding		 24.43M 26.85M 29.69M 34.53M 31.45M 34.93M 37.95M 37.89M 37.18M 44.15M 44.96M
Diluted Earnings per Share		 ($0.20) ($0.29) ($0.22) ($0.19) ($0.25) ($0.21) ($0.20) ($0.21) ($0.24) ($0.20) ($0.21)
Weighted Average Diluted Shares Outstanding		 24.43M 26.85M 29.69M 34.53M 31.45M 34.93M 37.95M 37.89M 37.18M 44.15M 44.96M
Weighted Average Basic & Diluted Shares Outstanding		 26.87M 27.00M 34.54M 34.54M 34.60M 37.73M 37.77M 38.05M 44.81M 44.84M 45.25M

Annual Cash Flow Statements for Genelux

This table details how cash moves in and out of Genelux's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -4.10 9.02 -0.85 -3.23
Net Cash From Operating Activities		 -3.57 -20 -21 -25
Net Cash From Continuing Operating Activities		 -3.57 -20 -21 -25
Net Income / (Loss) Continuing Operations		 -5.21 -28 -30 -32
Consolidated Net Income / (Loss)		 -5.21 -28 -30 -32
Depreciation Expense		 0.55 0.50 0.24 0.24
Non-Cash Adjustments To Reconcile Net Income		 2.52 10 7.66 7.91
Changes in Operating Assets and Liabilities, net		 -1.69 -3.28 0.75 -1.05
Net Cash From Investing Activities		 -0.05 -15 -8.13 12
Net Cash From Continuing Investing Activities		 -0.05 -15 -8.13 12
Purchase of Property, Plant & Equipment		 -0.05 -1.03 -0.38 -1.10
Purchase of Investments		 0.00 -14 -29 -18
Sale and/or Maturity of Investments		 - 0.00 21 32
Net Cash From Financing Activities		 -0.48 44 29 9.90
Net Cash From Continuing Financing Activities		 -0.48 44 29 9.90
Issuance of Common Equity		 0.12 43 29 9.88
Other Financing Activities, net		 -1.57 1.17 0.00 0.01

Quarterly Cash Flow Statements for Genelux

This table details how cash moves in and out of Genelux's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -20 -5.36 3.80 -1.76 2.46 7.64 -9.66 -1.85 0.64 3.94 -0.09
Net Cash From Operating Activities		 -6.91 -4.35 -6.82 -5.75 -4.30 -5.44 -7.06 -6.58 -6.20 -6.06 -6.44
Net Cash From Continuing Operating Activities		 -6.91 -4.35 -6.82 -5.86 -4.30 -5.44 -7.06 -6.58 -5.97 -6.06 -6.44
Net Income / (Loss) Continuing Operations		 -6.77 -7.85 -6.58 -6.47 -8.98 -7.49 -7.46 -7.95 -9.25 -8.93 -9.47
Consolidated Net Income / (Loss)		 -6.77 -7.85 -6.58 -6.47 -8.98 -7.49 -7.46 -7.95 -9.25 -8.93 -9.47
Depreciation Expense		 0.10 0.08 0.04 0.06 0.06 0.06 0.06 0.06 0.06 0.01 0.01
Amortization Expense		 -0.06 -0.15 -0.15 -0.25 -0.20 -0.14 -0.02 -0.03 - -0.07 -0.05
Non-Cash Adjustments To Reconcile Net Income		 1.83 2.96 1.61 1.81 1.93 1.61 1.56 2.72 2.01 1.87 2.19
Changes in Operating Assets and Liabilities, net		 -2.00 0.61 -1.74 -1.01 2.89 0.53 -1.21 -1.38 1.02 1.06 0.87
Net Cash From Investing Activities		 -14 -1.69 -17 3.99 6.67 3.51 -2.65 4.72 6.56 -8.54 5.97
Net Cash From Continuing Investing Activities		 -14 -1.69 -17 3.99 6.67 3.51 -2.65 4.72 6.56 -8.54 5.97
Purchase of Property, Plant & Equipment		 -0.24 -0.03 -0.23 -0.03 -0.10 -0.03 -0.12 -0.52 -0.44 -0.92 -1.53
Sale and/or Maturity of Investments		 - 1.50 6.50 6.00 7.25 6.00 8.00 11 7.00 6.78 7.50
Net Cash From Financing Activities		 0.40 0.69 28 - 0.09 9.57 0.05 - 0.28 19 0.39
Net Cash From Continuing Financing Activities		 0.40 0.69 28 - 0.09 9.57 0.05 - 0.28 19 0.39
Issuance of Common Equity		 0.25 0.69 28 - 0.09 9.55 0.05 0.01 0.26 19 0.39

Annual Balance Sheets for Genelux

This table presents Genelux's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 5.53 28 35 19
Total Current Assets		 1.89 24 32 15
Cash & Equivalents		 0.40 9.42 8.57 5.33
Short-Term Investments		 0.00 14 22 9.26
Prepaid Expenses		 1.50 1.01 0.65 0.54
Plant, Property, & Equipment, net		 0.64 1.17 1.32 2.17
Total Noncurrent Assets		 3.00 2.52 1.85 1.73
Other Noncurrent Operating Assets		 3.00 2.52 1.85 1.73
Total Liabilities & Shareholders' Equity		 5.53 28 35 19
Total Liabilities		 41 8.42 8.44 7.48
Total Current Liabilities		 32 6.55 6.90 6.23
Accounts Payable		 6.78 3.78 5.57 4.36
Other Taxes Payable		 2.85 2.12 - 1.44
Other Current Liabilities		 0.44 0.65 0.33 0.43
Total Noncurrent Liabilities		 9.69 1.87 1.54 1.26
Other Noncurrent Operating Liabilities		 1.16 1.87 1.54 1.26
Commitments & Contingencies		 - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -36 19 26 12
Total Preferred & Common Equity		 -36 19 26 12
Total Common Equity		 -36 19 26 12
Common Stock		 154 241 278 296
Retained Earnings		 -190 -222 -251 -284
Treasury Stock		 -0.43 -0.43 -0.43 -0.43
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.01 0.06 0.01

Quarterly Balance Sheets for Genelux

This table presents Genelux's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 34 25 45 40 39 32 25 32 26
Total Current Assets		 31 21 35 36 36 29 22 27 19
Cash & Equivalents		 30 4.06 7.86 6.10 16 6.55 - 9.27 9.18
Short-Term Investments		 - 16 26 28 19 21 16 17 9.49
Prepaid Expenses		 1.31 1.58 1.23 1.91 0.84 1.26 0.64 0.55 0.47
Plant, Property, & Equipment, net		 1.02 1.12 1.31 1.28 1.29 1.34 1.79 3.08 4.60
Total Noncurrent Assets		 1.87 2.36 9.00 3.03 1.75 1.67 1.64 2.54 2.46
Other Noncurrent Operating Assets		 1.87 2.36 2.19 2.02 1.75 1.67 1.64 2.54 2.46
Total Liabilities & Shareholders' Equity		 34 25 45 40 39 32 25 32 26
Total Liabilities		 10 9.59 7.51 7.18 9.14 8.35 6.40 9.45 10
Total Current Liabilities		 8.76 7.81 5.80 5.56 7.69 6.99 5.13 7.27 8.00
Accounts Payable		 4.01 5.31 4.79 4.45 6.69 6.03 3.99 6.10 6.92
Other Taxes Payable		 4.10 1.91 0.52 0.69 0.66 0.61 0.79 0.86 0.75
Other Current Liabilities		 0.57 0.58 0.50 0.42 0.34 0.35 0.35 0.32 0.33
Total Noncurrent Liabilities		 1.29 1.79 1.71 1.62 1.45 1.36 1.27 2.18 2.09
Other Noncurrent Operating Liabilities		 1.29 1.79 1.71 1.62 1.45 1.36 1.27 2.18 2.09
Commitments & Contingencies		 - - - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 24 15 38 33 30 24 19 23 16
Total Preferred & Common Equity		 24 15 38 33 30 24 19 23 16
Total Common Equity		 24 15 38 33 30 24 19 23 16
Common Stock		 239 245 274 276 289 291 293 316 318
Retained Earnings		 -215 -229 -236 -242 -259 -266 -274 -292 -302
Treasury Stock		 -0.43 -0.43 -0.43 -0.43 -0.43 -0.43 -0.43 -0.43 -0.43
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 -0.01 0.12 0.03 0.00 0.01 -0.01 -0.00

Annual Metrics And Ratios for Genelux

This table displays calculated financial ratios and metrics derived from Genelux's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 26,717,676.00 - 38,051,771.00
DEI Adjusted Shares Outstanding		 0.00 26,717,676.00 - 38,051,771.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.06 - -0.84
Growth Metrics		 - - - -
Revenue Growth		 0.00% -98.46% -95.29% 0.00%
EBITDA Growth		 0.00% -1,289.35% -18.53% -7.51%
EBIT Growth		 0.00% -912.12% -11.90% -7.48%
NOPAT Growth		 0.00% -702.02% -31.16% -4.79%
Net Income Growth		 0.00% -443.44% -5.56% -7.62%
EPS Growth		 0.00% -103.51% 18.10% 9.47%
Operating Cash Flow Growth		 0.00% -467.77% -4.70% -19.03%
Free Cash Flow Firm Growth		 0.00% 0.00% 8.56% -16.61%
Invested Capital Growth		 0.00% 63.11% -24.29% 33.98%
Revenue Q/Q Growth		 0.00% -28.57% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -18.64% -6.13% 0.59%
EBIT Q/Q Growth		 0.00% -16.69% -5.60% -0.61%
NOPAT Q/Q Growth		 0.00% -19.29% -9.49% 1.00%
Net Income Q/Q Growth		 0.00% -13.07% -7.99% -0.85%
EPS Q/Q Growth		 0.00% 0.00% -5.56% 1.15%
Operating Cash Flow Q/Q Growth		 0.00% -36.23% 10.94% -8.12%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 11.67% -7.31%
Invested Capital Q/Q Growth		 0.00% 35.91% -134.69% -31.28%
Profitability Metrics		 - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -17.06% -15,430.00% -388,637.50% -407,650.00%
Operating Margin		 -27.22% -14,214.71% -396,200.00% -415,175.00%
EBIT Margin		 -24.39% -16,068.82% -382,112.50% -410,700.00%
Profit (Net Income) Margin		 -47.05% -16,645.29% -373,362.50% -401,812.50%
Tax Burden Percent		 126.78% 100.39% 100.00% 100.00%
Interest Burden Percent		 152.17% 103.18% 97.71% 97.84%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 14.55% 346.99% -130.58% -170.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -48.80% -163.46% -97.65% -122.27%
Return on Assets (ROA)		 -94.14% -169.32% -95.41% -119.62%
Return on Common Equity (ROCE)		 14.56% 347.46% -130.58% -170.00%
Return on Equity Simple (ROE_SIMPLE)		 14.55% -145.31% -113.68% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.11 -17 -22 -23
NOPAT Margin		 -19.06% -9,950.29% -277,340.00% -290,622.50%
Net Nonoperating Expense Percent (NNEP)		 12.05% 905.81% -28.41% -39.11%
Return On Investment Capital (ROIC_SIMPLE)		 - -86.87% -84.45% -201.40%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 45.20% 6,804.71% 158,825.00% 167,137.50%
R&D to Revenue		 82.02% 7,510.00% 237,475.00% 248,137.50%
Operating Expenses to Revenue		 127.22% 14,314.71% 396,300.00% 415,275.00%
Earnings before Interest and Taxes (EBIT)		 -2.70 -27 -31 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.89 -26 -31 -33
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 19.22 3.10 14.37
Price to Tangible Book Value (P/TBV)		 0.00 19.22 3.10 14.37
Price to Revenue (P/Rev)		 1.36 2,201.85 10,188.76 20,738.22
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.57 2,065.43 6,326.89 18,913.84
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 -0.70 0.00 0.00 0.00
Long-Term Debt to Equity		 -0.24 0.00 0.00 0.00
Financial Leverage		 -0.72 -0.15 -1.18 -1.20
Leverage Ratio		 -0.15 -2.05 1.37 1.42
Compound Leverage Factor		 -0.24 -2.11 1.34 1.39
Debt to Total Capital		 -229.49% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -151.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -78.49% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 -0.20% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 329.70% 100.00% 100.00% 100.00%
Debt to EBITDA		 -13.20 0.00 0.00 0.00
Net Debt to EBITDA		 -12.99 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -4.51 0.00 0.00 0.00
Debt to NOPAT		 -11.82 0.00 0.00 0.00
Net Debt to NOPAT		 -11.63 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -4.04 0.00 0.00 0.00
Altman Z-Score		 -53.88 13.09 -6.40 -12.70
Noncontrolling Interest Sharing Ratio		 -0.06% -0.13% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.06 3.69 4.57 2.43
Quick Ratio		 0.01 3.54 4.48 2.34
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -23 -21 -25
Operating Cash Flow to CapEx		 -7,287.76% -1,978.05% -5,571.65% -2,301.28%
Free Cash Flow to Firm to Interest Expense		 0.00 -22.15 0.00 0.00
Operating Cash Flow to Interest Expense		 -2.54 -19.29 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2.57 -20.27 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 2.00 0.01 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 17.19 0.19 0.01 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 -10 -3.72 -4.62 -3.05
Invested Capital Turnover		 -1.10 -0.02 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 6.36 -0.90 1.57
Enterprise Value (EV)		 40 351 51 151
Market Capitalization		 15 374 82 166
Book Value per Share		 ($3.93) $0.73 $0.76 $0.30
Tangible Book Value per Share		 ($3.93) $0.73 $0.76 $0.30
Total Capital		 -11 19 26 12
Total Debt		 25 0.00 0.00 0.00
Total Long-Term Debt		 8.52 0.00 0.00 0.00
Net Debt		 25 -23 -31 -15
Capital Expenditures (CapEx)		 0.05 1.03 0.38 1.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -5.54 -6.25 -5.69
Debt-free Net Working Capital (DFNWC)		 -13 18 25 8.91
Net Working Capital (NWC)		 -30 18 25 8.91
Net Nonoperating Expense (NNE)		 3.10 11 7.68 8.90
Net Nonoperating Obligations (NNO)		 26 -23 -31 -15
Total Depreciation and Amortization (D&A)		 0.81 1.09 -0.52 0.24
Debt-free, Cash-free Net Working Capital to Revenue		 -124.07% -3,260.00% -78,125.00% -71,125.00%
Debt-free Net Working Capital to Revenue		 -120.48% 10,381.76% 308,062.50% 111,312.50%
Net Working Capital to Revenue		 -268.65% 10,381.76% 308,062.50% 111,312.50%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.16) ($0.95) ($0.86)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 24.43M 31.45M 37.18M
Adjusted Diluted Earnings per Share		 $0.00 ($1.16) ($0.95) ($0.86)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 24.43M 31.45M 37.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 26.87M 34.60M 44.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.11 -17 -22 -23
Normalized NOPAT Margin		 -19.06% -9,950.29% -277,340.00% -290,622.50%
Pre Tax Income Margin		 -37.11% -16,580.00% -373,362.50% -401,812.50%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -1.92 -25.99 0.00 0.00
NOPAT to Interest Expense		 -1.50 -16.09 0.00 0.00
EBIT Less CapEx to Interest Expense		 -1.95 -26.97 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -1.53 -17.07 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Genelux

This table displays calculated financial ratios and metrics derived from Genelux's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 26,717,676.00 26,865,473.00 26,996,740.00 34,535,471.00 - 34,604,296.00 37,734,967.00 37,773,443.00 38,051,771.00 44,805,811.00 44,840,416.00
DEI Adjusted Shares Outstanding		 26,717,676.00 26,865,473.00 26,996,740.00 34,535,471.00 - 34,604,296.00 37,734,967.00 37,773,443.00 38,051,771.00 44,805,811.00 44,840,416.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.25 -0.29 -0.24 -0.19 - -0.22 -0.20 -0.21 -0.24 -0.20 -0.21
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -95.29% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -144.83% 8.60% -30.30% -32.00% -25.79% 3.41% -11.38% -17.56% -2.14% -18.11% -26.20%
EBIT Growth		 -126.28% 16.80% -24.91% -25.05% -23.14% 3.62% -13.96% -21.47% -2.16% -18.56% -24.97%
NOPAT Growth		 -126.28% -25.58% -27.75% -30.79% -39.24% 3.68% -13.06% -18.05% 3.45% -17.34% -23.78%
Net Income Growth		 -93.62% 24.26% -12.97% -20.99% -32.64% 4.56% -13.38% -22.93% -3.02% -19.17% -27.03%
EPS Growth		 0.00% 45.28% 4.35% 5.00% -25.00% 27.59% 9.09% -10.53% 4.00% 4.76% -5.00%
Operating Cash Flow Growth		 -355.20% 5.14% -25.95% -71.22% 37.74% -24.83% -3.44% -14.39% -44.10% -11.48% 8.71%
Free Cash Flow Firm Growth		 0.00% -619.14% -792.46% -516.60% 47.43% 32.14% 38.85% 38.09% -37.80% -76.28% -98.74%
Invested Capital Growth		 63.11% 22.66% 41.58% 66.06% -24.29% -15.69% -46.55% -18.03% 33.98% 37.44% 37.24%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00%
EBITDA Q/Q Growth		 -33.59% -15.26% 14.66% -0.45% -22.81% 14.95% 1.59% -6.03% -15.09% 1.64% -5.15%
EBIT Q/Q Growth		 -30.88% -13.76% 15.38% 0.74% -24.20% 16.36% -0.05% -5.79% -15.38% 2.92% -5.46%
NOPAT Q/Q Growth		 -31.92% -15.91% 15.07% -0.71% -40.44% 19.82% 0.31% -5.16% -14.86% 2.56% -5.17%
Net Income Q/Q Growth		 -26.60% -16.00% 16.23% 1.66% -38.80% 16.53% 0.48% -6.63% -16.31% 3.45% -6.08%
EPS Q/Q Growth		 0.00% -45.00% 24.14% 13.64% -31.58% 16.00% 4.76% -5.00% -14.29% 16.67% -5.00%
Operating Cash Flow Q/Q Growth		 -105.84% 36.99% -56.73% 15.77% 25.16% -26.34% -29.88% 6.86% 5.72% 2.26% -6.35%
Free Cash Flow Firm Q/Q Growth		 -639.84% 37.74% 2.97% -27.74% 31.87% 19.63% 12.56% -29.33% -51.62% -2.81% 1.42%
Invested Capital Q/Q Growth		 35.91% -22.19% 38.81% 29.17% -134.69% -13.74% 22.49% 42.96% -31.28% -7.77% 22.23%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin		 0.00% -100,387.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -116,437.50% 0.00% 0.00%
Operating Margin		 0.00% -101,437.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -117,650.00% 0.00% 0.00%
EBIT Margin		 0.00% -99,550.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -117,187.50% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -98,125.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -115,587.50% 0.00% 0.00%
Tax Burden Percent		 101.67% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.07% 98.57% 97.58% 96.68% 104.12% 97.60% 97.08% 97.85% 98.63% 98.10% 98.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 346.99% -290.10% -88.57% -96.85% -130.58% -131.36% -98.73% -123.35% -170.00% -127.28% -177.93%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -40.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -34.89% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -39.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -34.41% 0.00% 0.00%
Return on Common Equity (ROCE)		 347.46% -290.10% -88.57% -96.85% -130.58% -131.36% -98.73% -123.35% -170.00% -127.28% -177.93%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -170.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.90 -5.68 -4.82 -4.86 -6.82 -5.47 -5.45 -5.74 -6.59 -6.42 -6.75
NOPAT Margin		 0.00% -71,006.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -82,355.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 148.53% -15.39% -5.19% -4.96% -7.96% -7.38% -5.85% -7.91% -11.69% -8.18% -11.66%
Return On Investment Capital (ROIC_SIMPLE)		 -25.17% -37.66% -12.81% -14.68% -25.97% -18.33% -22.82% -30.85% -57.07% -28.01% -41.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 51,412.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 47,075.00% 0.00% 0.00%
R&D to Revenue		 0.00% 50,125.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 70,675.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 101,537.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 117,750.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.00 -7.96 -6.74 -6.69 -8.62 -7.68 -7.68 -8.13 -9.38 -9.10 -9.60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.97 -8.03 -6.85 -6.89 -8.77 -7.76 -7.63 -8.09 -9.32 -9.16 -9.63
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 19.22 11.45 1.40 2.47 3.10 3.13 4.53 8.53 14.37 4.73 8.38
Price to Tangible Book Value (P/TBV)		 19.22 11.45 1.40 2.47 3.10 3.13 4.53 8.53 14.37 4.73 8.38
Price to Revenue (P/Rev)		 2,201.85 21,593.12 6,580.46 10,231.13 10,188.76 0.00 0.00 0.00 20,738.22 13,553.76 16,871.21
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2,065.43 19,139.75 1,524.33 5,848.63 6,326.89 0.00 0.00 0.00 18,913.84 10,277.63 14,537.46
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.15 -1.59 -1.13 -1.14 -1.18 -1.22 -1.11 -1.08 -1.20 -1.16 -1.17
Leverage Ratio		 -2.05 2.21 1.28 1.30 1.37 1.42 1.26 1.26 1.42 1.35 1.46
Compound Leverage Factor		 -1.95 2.18 1.25 1.26 1.42 1.38 1.22 1.24 1.40 1.33 1.44
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 15.49 -2.62 -2.83 -1.23 -4.31 -2.94 -3.74 -0.77 -8.62 -5.97 -8.80
Noncontrolling Interest Sharing Ratio		 -0.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.69 2.72 6.01 6.47 4.57 4.67 4.18 4.20 2.43 3.68 2.39
Quick Ratio		 3.54 2.51 5.80 6.13 4.48 4.57 4.00 3.16 2.34 3.60 2.33
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -7.01 -6.80 -8.69 -5.92 -4.76 -4.16 -5.38 -8.16 -8.39 -8.27
Operating Cash Flow to CapEx		 -2,843.62% -14,513.33% -2,992.98% -21,288.89% -4,481.25% -18,116.67% -6,138.26% -1,271.76% -1,421.79% -657.87% -420.63%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.19 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.72 -4.54 -2.78 -1.97 -4.62 -5.26 -4.07 -2.32 -3.05 -3.29 -2.56
Invested Capital Turnover		 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 6.36 1.33 1.98 3.83 -0.90 -0.71 -1.29 -0.36 1.57 1.97 1.52
Enterprise Value (EV)		 351 153 12 47 51 58 80 138 151 82 116
Market Capitalization		 374 173 53 82 82 93 108 159 166 108 135
Book Value per Share		 $0.73 $0.56 $1.40 $0.96 $0.76 $0.86 $0.63 $0.49 $0.30 $0.51 $0.36
Tangible Book Value per Share		 $0.73 $0.56 $1.40 $0.96 $0.76 $0.86 $0.63 $0.49 $0.30 $0.51 $0.36
Total Capital		 19 15 38 33 26 30 24 19 12 23 16
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -23 -20 -40 -35 -31 -35 -28 -21 -15 -26 -19
Capital Expenditures (CapEx)		 0.24 0.03 0.23 0.03 0.10 0.03 0.12 0.52 0.44 0.92 1.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.54 -6.23 -4.57 -3.65 -6.25 -6.85 -5.73 -4.49 -5.69 -6.73 -7.52
Debt-free Net Working Capital (DFNWC)		 18 13 29 30 25 28 22 16 8.91 19 11
Net Working Capital (NWC)		 18 13 29 30 25 28 22 16 8.91 19 11
Net Nonoperating Expense (NNE)		 1.87 2.17 1.75 1.61 2.15 2.02 2.00 2.21 2.66 2.51 2.72
Net Nonoperating Obligations (NNO)		 -23 -20 -40 -35 -31 -35 -28 -21 -15 -26 -19
Total Depreciation and Amortization (D&A)		 0.03 -0.07 -0.12 -0.20 -0.14 -0.08 0.05 0.03 0.06 -0.06 -0.04
Debt-free, Cash-free Net Working Capital to Revenue		 -3,260.00% -77,850.00% -57,112.50% -45,562.50% -78,125.00% 0.00% 0.00% 0.00% -71,125.00% -84,087.50% -94,050.00%
Debt-free Net Working Capital to Revenue		 10,381.76% 167,487.50% 363,337.50% 380,150.00% 308,062.50% 0.00% 0.00% 0.00% 111,312.50% 243,525.00% 139,325.00%
Net Working Capital to Revenue		 10,381.76% 167,487.50% 363,337.50% 380,150.00% 308,062.50% 0.00% 0.00% 0.00% 111,312.50% 243,525.00% 139,325.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.29) ($0.22) ($0.19) ($0.25) ($0.21) ($0.20) ($0.21) ($0.24) ($0.20) ($0.21)
Adjusted Weighted Average Basic Shares Outstanding		 24.43M 26.85M 29.69M 34.53M 31.45M 34.93M 37.95M 37.89M 37.18M 44.15M 44.96M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.29) ($0.22) ($0.19) ($0.25) ($0.21) ($0.20) ($0.21) ($0.24) ($0.20) ($0.21)
Adjusted Weighted Average Diluted Shares Outstanding		 24.43M 26.85M 29.69M 34.53M 31.45M 34.93M 37.95M 37.89M 37.18M 44.15M 44.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.87M 27.00M 34.54M 34.54M 34.60M 37.73M 37.77M 38.05M 44.81M 44.84M 45.25M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.90 -5.68 -4.82 -4.86 -6.82 -5.47 -5.45 -5.74 -6.59 -6.42 -6.75
Normalized NOPAT Margin		 0.00% -71,006.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -82,355.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -98,125.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -115,587.50% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Genelux (NASDAQ:GNLX) remains a pre-revenue biotechnology company with substantial research spending, recurring operating losses and ongoing reliance on equity financing. The latest quarter showed no operating revenue and a net loss of $9.5 million, compared with losses of $8.9 million in Q1 2026 and $7.5 million in Q2 2025.

  • Genelux maintains a liquid balance sheet. As of June 30, 2026, the company held $9.2 million in cash and $9.5 million in short-term investments. Current assets of $19.1 million exceeded current liabilities of $8.0 million, producing a current ratio of approximately 2.4.
  • Debt levels remain limited. The balance sheet lists no material short-term or long-term debt, reducing interest-rate and debt-refinancing risk. Total liabilities were $10.1 million versus shareholders’ equity of $16.1 million.
  • Investment income provides a modest offset to operating losses. Interest and investment income totaled $127,000 in Q2 2026, while total other income was $174,000. These amounts do not materially change the company’s loss profile but provide some support for cash resources.
  • Genelux continues investing in its development platform. Capital expenditures increased to $1.5 million in Q2 2026 from $921,000 in Q1, suggesting continued investment in property, equipment and research infrastructure.
  • Cash management has involved significant investment purchases and maturities. The company generated $7.5 million from investment sales or maturities in Q2 2026, more than offsetting $1.5 million of capital expenditures and helping produce $6.0 million of investing cash flow. This activity improves near-term liquidity, but it is not recurring operating revenue.
  • Non-cash adjustments materially reduce the gap between net loss and operating cash burn. Q2 2026 included $2.2 million of non-cash adjustments and $871,000 from changes in operating assets and liabilities. Investors should distinguish these accounting adjustments from cash generated by the business.
  • Operating cash flow remains consistently negative. Genelux used $6.4 million in operating cash during Q2 2026, following outflows of $6.1 million in Q1 2026, $6.0 million in Q4 2025 and $7.1 million in Q2 2025. The company has not demonstrated a path to self-funded operations.
  • Quarterly operating expenses are rising. Total operating expenses increased to $9.6 million in Q2 2026 from $9.2 million in Q1 and $7.8 million in Q2 2025. Research and development expense rose to $6.5 million, while selling, general and administrative expense was $3.1 million.
  • The company has reported little to no revenue across the period provided. Revenue was $0 in Q2 2026, Q1 2026, Q3 2025 and Q2 2025, with only nominal revenue reported in several earlier quarters. As a result, operating income was negative $9.6 million in the latest quarter.
  • Genelux remains dependent on issuing stock to fund operations. The company raised $18.5 million through common-equity issuance in Q1 2026 and another $387,000 in Q2. Weighted-average basic shares increased to approximately 45.0 million in Q2 2026 from 38.0 million in Q2 2025, creating dilution risk for existing shareholders.

At the Q2 2026 operating cash-burn rate, the company’s $18.7 million of cash and short-term investments represented roughly three quarters of liquidity before considering future financing, investment returns or changes in spending. The key issues for investors are whether Genelux can advance its pipeline toward commercialization, reduce its quarterly cash burn and obtain additional funding without substantial shareholder dilution.

10/09/26 06:34 PM ETAI Generated. May Contain Errors.

Genelux Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Genelux's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Genelux's net income appears to be on a downward trend, with a most recent value of -$32.15 million in 2025, falling from -$5.21 million in 2022. The previous period was -$29.87 million in 2024. View Genelux's forecast to see where analysts expect Genelux to go next.

Genelux's total operating income in 2025 was -$33.21 million, based on the following breakdown:
  • Total Gross Profit: $8 thousand
  • Total Operating Expenses: $33.22 million

Over the last 3 years, Genelux's total revenue changed from $11.07 million in 2022 to $8 thousand in 2025, a change of -99.9%.

In the past 11 quarters, Genelux's cash and equivalents has ranged from $0.00 in Q3 2025 to $29.87 million in Q3 2023, and is currently $9.18 million as of their latest financial filing in Q2 2026.

Genelux had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2022.

Over the last 3 years, Genelux's book value per share changed from -3.93 in 2022 to 0.30 in 2025.


Related Companies

Financial statements for NASDAQ:GNLX last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel